NASDAQ:FATE - Fate Therapeutics Stock Price, News & Analysis

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) issued its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.04. The biopharmaceutical company earned $2.80 million during the quarter, compared to analyst estimates of $1.09 million. Fate Therapeutics had a negative net margin of 934.70% and a negative return on equity of 50.05%. The company's revenue for the quarter was up 180.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.37) earnings per share. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Fate Therapeutics.

15 brokerages have issued 12-month price objectives for Fate Therapeutics' stock. Their forecasts range from $17.00 to $32.00. On average, they expect Fate Therapeutics' stock price to reach $25.00 in the next year. This suggests a possible upside of 34.6% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

Media stories about FATE stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fate Therapeutics earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include Repligen (RGEN), argenx (ARGX), Moderna (MRNA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Regenxbio (RGNX) and Coherus Biosciences (CHRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Neurocrine Biosciences (NBIX), Portola Pharmaceuticals (PTLA), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL) and Tandem Diabetes Care (TNDM).

Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.92%), Victory Capital Management Inc. (4.48%), Vanguard Group Inc. (4.17%), Artal Group S.A. (2.30%), Price T Rowe Associates Inc. MD (1.82%) and Arch Venture Corp (1.49%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Artal Group S.A., Eversept Partners LP, Lisanti Capital Growth LLC, Price T Rowe Associates Inc. MD, Westfield Capital Management Co. LP, Alps Advisors Inc. and Bank of New York Mellon Corp. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Wells Fargo & Company MN, Nuveen Asset Management LLC and ARK Investment Management LLC. View Insider Buying and Selling for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $18.57.

Fate Therapeutics has a market capitalization of $1.21 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]